Johnson & Johnson Raises Full-Year Revenue Guidance to $100.3–101.3 Billion and Signs Surgical Training Partnership with RCS

Economic Observer NetworkJohnson & Johnson Signs Strategic Cooperation Agreement with The Royal College of Surgeons of England, Raises Full-Year 2026 Revenue Guidance, and Advances Localization Strategy to Address Policy Pressures

Surgical Training Collaboration:

On May 8, 2026, Johnson & Johnson Medical Technology and the Royal College of Surgeons (RCS) signed a new round of strategic cooperation agreement, and launched the "RCS England-China Working Group", aiming to build a global surgical skills training system, especially in surgery.Robotand other emerging fields。

Performance and Operation:

Based on the better-than-expected performance of $24.1 billion in revenue for the first quarter of 2026, representing a 9.9% year-over-year increase, Johnson & Johnson has raised its full-year 2026 revenue guidance to a range of $100.3 billion to $101.3 billion, which is expected to surpass the $100 billion mark for the first time.。

Business Progress:

Growth momentum mainly comes from innovative pharmaceuticals businesses (such as Darzalex, Tremfya and other drugs) and the cardiovascular field in medical technology business (such as electrophysiology products). However, drugs like Stelara are facing sales slowdown pressure due to patent expiration.。

China Market Layout:

The company continues to push forward with its localization strategy in the Chinese market and needs to address price pressures brought on by policies such as Volume-Based Procurement (VBP) for medical devices.。

The above content is based on publicly available information and does not constitute investment advice.